| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
NeuroSense Therapeutics Ltd.$0.73
-0.01 (-0.89%)
D 23Pipeline Score Richly Valued Pharma · Clinical
Market Cap
28.99 M
EPS
-
P/E Ratio
-
Value Trade
72.39 K
-3.8 %
Week
13.89 %
1 Month
-7.5 %
3 Month
-23.36 %
6 Month
-81.98 %
5 Year
-81.98 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
56.15 K
52 Week Range
0.63 - 2.60
% held by Insiders
34.02 %
% held by Institutions
1.07 %
Enterprise Value
28.94 M
Total Shares
32.55 M
Short %
2.75 %
Float Shares
21.25 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NeuroSense Therapeutics Ltd.
412Total events
2Upcoming
93Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
Event history 410
Jul 8, 2026
◆Oral PresentationPresentation
NeuroSense to participate in Roth-hosted KOL webinar on ALS treatment
ALSsource ↗
Jul 6, 2026
▲Trial InitiationPrimeCTrial
FDA clearance to initiate pivotal Phase 3 PARAGON trial of PrimeC in ALS
ALSsource ↗
Jun 24, 2026
◆Oral PresentationPrimeCPresentation
EverythingALS community event discussing emerging data on PrimeC
ALSsource ↗
Jun 11, 2026
▲Patent GrantedPrimeCIP / Competition
South Korean patent granted covering PrimeC composition for ALS
amyotrophic lateral sclerosis (ALS)source ↗
Jun 9, 2026
▲Patent GrantedPrimeCIP / Competition
Japanese Patent 7857044 granted for PrimeC composition and formulation
amyotrophic lateral sclerosis (ALS)source ↗
Jun 2026
◆NDA SubmissionPrimeCRegulatory Filing
Potential NDS submission to Health Canada
amyotrophic lateral sclerosis (ALS)source ↗
May 2026
◆Pre NDA MeetingPrimeCFDA Meeting
Pre-NDS meeting with Health Canada rescheduled to May 2026
ALSsource ↗
Apr 6, 2026
▲Patent GrantedPrimeCIP / Competition
Brazilian patent granted covering PrimeC composition
ALS, Alzheimer's diseasesource ↗
Apr 2, 2026
▼Quarterly UpdateCorporate
Received Nasdaq notification for minimum market value of listed securities non-compliance
Apr 2026
◆Topline ReadoutPrimeCClinical Data
Clinical and biomarker results from Alzheimer's study expected in coming weeks
Alzheimer's diseasesource ↗
Drug Pipeline Intelligence
D23
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 21%
Micro Cap (rank 721 of 911)
Percentile RankNeuroSense Therapeutics Ltd. faces pipeline headwinds (23/100), with $98M risk-adjusted pipeline value, led by PrimeC- in Pharmacokinetics (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PrimeC Small molecule | Amyotrophic Lateral Sclerosis | Phase 2 | NCT05357950 | 21% | $76M | COMPLETED | 69 | - | - | Nov 4, 2024 | - | Sep 5, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PrimeC Orphan | amyotrophic lateral sclerosis (ALS) | Phase 2b | 2026-06-22 | meaningful survival benefit | EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots Read More | |
PrimeC Orphan | amyotrophic lateral sclerosis (ALS) | Phase 2b | 2026-06-22 | meaningful survival benefit | EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots Read More | |
PrimeC Orphan | amyotrophic lateral sclerosis (ALS) | Phase 2b | 2026-06-22 | meaningful survival benefit | EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NRSN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NRSN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NRSNNeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
NeuroSense Therapeutics will participate in a KOL webinar hosted by Roth Capital Partners to discuss ALS treatment advancements. The webinar will feature experts addressing unmet needs in ALS, trial design, and the company's PrimeC therapy. NeuroSense's PrimeC has shown promising results in previous studies and aims for FDA accelerated approval in its upcoming Phase 3 trial.
Read more →NRSNEverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
NeuroSense Therapeutics will participate in a community event hosted by EverythingALS to discuss emerging data on PrimeC, its lead drug candidate for ALS. The event will feature Prof. Jeffrey Rosenfeld and CEO Alon Ben-Noon, focusing on the latest developments in ALS research. NeuroSense has recently received FDA clearance to initiate a pivotal Phase 3 trial for PrimeC.
Read more →NRSNNeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands intellectual property protection in one of the
NeuroSense Therapeutics has been granted a South Korean patent for PrimeC, its lead drug candidate aimed at treating amyotrophic lateral sclerosis (ALS). The patent, which covers the formulation, manufacturing process, and pharmacokinetic characteristics of PrimeC, provides protection through 2042. This milestone is significant as it expands NeuroSense's global intellectual property offerings and supports the development and commercialization of PrimeC, which has shown promising results in earlier studies. The company is preparing for a pivotal Phase 3 trial following successful outcomes in prior stages, signaling potential advances in ALS treatment.
Read more →NRSNNeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
NeuroSense Therapeutics has received a Japanese patent for its lead drug candidate, PrimeC, which targets amyotrophic lateral sclerosis (ALS). The patent, effective until 2042, covers the unique formulation and manufacturing process. This development supports the company's strategy as it prepares for a pivotal Phase 3 clinical trial following positive results from earlier studies. The patent enhances NeuroSense's global intellectual property portfolio.
Read more →NRSN▲ +7.8%on this news· ran to +19% by day 3
NeuroSense Announces Pricing of Insider-Led PIPE Financing
NeuroSense Therapeutics has announced a PIPE financing agreement to raise $600,000 through the sale of 750,000 ordinary shares at $0.80 each. The financing is led by CEO Alon Ben-Noon and CFO Or Eisenberg, with participation from a significant existing shareholder. The funds will be used for general corporate purposes ahead of clinical milestones.
Read more →NRSN▼ -8.2%on this news
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
NeuroSense Therapeutics has been granted a Brazilian patent for its PrimeC composition, which combines ciprofloxacin and celecoxib. This patent, valid until October 2042, strengthens the company's global intellectual property portfolio. The announcement follows positive results from a Phase 2b trial, with plans for a Phase 3 pivotal trial for ALS underway.
Read more →NRSN▼ -8.2%on this newsshared move
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
NeuroSense Therapeutics has received notifications from Nasdaq regarding non-compliance with listing requirements due to its stock price and market value falling below the necessary thresholds. The company has a compliance period until September 29, 2026, to rectify these issues. Despite the notifications, trading of its securities will continue on Nasdaq.
Read more →NRSNNeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
NeuroSense Therapeutics reported its 2025 financial results, highlighting significant progress in its PrimeC program, which has advanced to late-stage clinical development. The company demonstrated promising survival data from its Phase 2b study and received FDA clearance for a Phase 3 trial in ALS. Despite financial challenges, NeuroSense's advancements position it favorably within the neurodegenerative disease treatment landscape.
Read more →NRSNNeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
NeuroSense Therapeutics has announced key regulatory updates for its lead drug candidate, PrimeC, including a rescheduled pre-NDS meeting with Health Canada to incorporate new data. The company expects to release results from its Alzheimer's study soon and has received FDA clearance for a pivotal Phase 3 trial in ALS. These developments position NeuroSense for significant milestones in 2026.
Read more →NRSN▼ -5.4%on this news
/C O R R E C T I O N -- NeuroSense/
NeuroSense Therapeutics announced that Dr. Christian Lunetta will present new findings on their investigational therapy PrimeC for ALS at the upcoming AD/PD 2026 Conference. The presentation will highlight key clinical insights from the Phase 2b PARADIGM trial, informing the design of the global Phase 3 PARAGON trial. NeuroSense aims to provide effective treatments for ALS, which poses significant unmet medical needs. Additionally, the company is actively engaging with regulatory authorities to facilitate PrimeC's path towards potential marketing authorization.
Read more →NRSN▼ -5.6%on this newsshared move
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity The Journal of the American Medical Association (JAMA Neurology) publicati
NeuroSense Therapeutics has announced the publication of results from its Phase 2b trial of PrimeC in ALS in JAMA Neurology, indicating positive clinical outcomes. The trial demonstrated a slower functional decline and reduced risk of ALS-related complications among participants. Findings highlighted both clinical and biomarker improvements, bolstering the scientific rationale for further development of PrimeC. A Phase 3 trial has been given FDA clearance and aims to evaluate the long-term benefits of the therapy.
Read more →NRSNPrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
NeuroSense Therapeutics announced that long-term survival data from its Phase 2b PARADIGM trial of PrimeC for ALS will be presented at a scientific conference on March 9, 2026. The data reveals a 65% reduction in risk of death and a median survival benefit exceeding 14 months. Presented by Dr. Jinsy Andrews, the findings underscore the efficacy and safety of PrimeC, reinforcing its continued development towards regulatory approval. NeuroSense is actively engaging with regulatory authorities for the next phase of clinical trials.
Read more →NRSN▼ -14.7%on this news
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in
NeuroSense Therapeutics announced long-term survival data from its PARADIGM Phase 2b trial for PrimeC in ALS patients. The updated analysis shows a statistically significant 65% reduction in risk of death and an increase in median survival by over 14 months compared to placebo. The findings reinforce PrimeC's potential as a disease-modifying therapy, with consistent results seen throughout the trial follow-up period. These results also strengthen NeuroSense's position as they advance toward late-stage development.
Read more →NRSNHamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 10, 2026 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend a Special Meeti
NeuroSense Therapeutics Ltd. has announced a Special Meeting of Shareholders scheduled for March 10, 2026, at their offices in Herzliya, Israel. Shareholders of record as of February 17, 2026, are invited to participate and cast their votes on unspecified proposals to be detailed in the Proxy Statement. The Board of Directors recommends voting in favor of the proposals. The notice outlines the voting instructions and important deadlines for proxy submissions.
Read more →NRSN▲ +8.5%on this news
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Therapeutics has secured an Australian patent for its drug PrimeC, which combines ciprofloxacin and celecoxib, enhancing its global intellectual property strategy. This patent follows a similar approval in the U.S. and extends protection until 2042. PrimeC is ready for Phase 3 trials in ALS, following promising Phase 2b results.
Read more →NRSN▼ -5.2%on this news
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Therapeutics has been granted a U.S. patent for its PrimeC combination therapy aimed at treating Alzheimer's disease. The patent, which extends protection until 2043, reinforces the company's intellectual property and supports its long-term development strategy. Recent proof-of-concept study results indicate a favorable safety profile, with further clinical and biomarker data expected soon.
Read more →NRSN▲ +12.4%on this news· ran to +31% by day 3
World-Renowned Alzheimer
NeuroSense Therapeutics has announced the addition of Prof. Steven E. Arnold to its Scientific Advisory Board, bolstering its expertise in Alzheimer's research. The company expects to report clinical and biomarker outcomes from its recent Alzheimer's study, which demonstrated a favorable safety profile for its drug candidate, PrimeC, in Q1 2026. PrimeC aims to address multiple mechanisms involved in neurodegeneration associated with Alzheimer's and ALS, reflecting NeuroSense's strategy of developing combined therapies for complex neurodegenerative diseases.
Read more →NRSNNeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026
NeuroSense Therapeutics has completed a favorable safety analysis of its Phase 2 study for PrimeC, a combination therapy targeting Alzheimer's disease. The study did not report any serious adverse events, indicating a positive tolerability profile. Clinical and biomarker outcome measures are expected to be provided in Q1 2026, which aims to gauge the therapeutic potential of PrimeC. NeuroSense is focused on addressing the unmet medical needs associated with neurodegenerative diseases, including Alzheimer's.
Read more →NRSNNeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense Therapeutics is set to hold a pre-NDS meeting with Health Canada in April 2026, following a productive discussion that confirmed alignment on regulatory steps for its ALS treatment, PrimeC. The company anticipates a potential NDS submission by mid-2026, contingent on the meeting's outcome. This engagement has reinforced the company's confidence in its regulatory pathway.
Read more →NRSN▼ -5.7%on this news
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Therapeutics has received FDA clearance to start a pivotal Phase 3 trial for its drug candidate PrimeC, aimed at treating ALS. The trial, named PARAGON, will involve 300 participants and is designed to build on promising results from a previous Phase 2b trial. NeuroSense is preparing for trial initiation and plans to enroll the first patient soon.
Read more →NRSNHamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 30, 2025 ________________________ Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite y
NeuroSense Therapeutics Ltd. has called a Special Meeting of Shareholders to be held on December 30, 2025. Key agenda items include granting restricted shares to non-management directors and the CEO for 2024, aimed at maintaining financial flexibility. The Board of Directors recommends shareholders vote in favor of these proposals. The notice provides details on proxy voting to ensure all shareholders have the opportunity to participate.
Read more →NRSNNeuroSense to Host Investor Webinar on December 8, 2025
NeuroSense Therapeutics Ltd. will host an investor webinar on December 8, 2025, to provide updates on its clinical and regulatory progress. The company focuses on developing treatments for severe neurodegenerative diseases, addressing significant unmet medical needs. Investors can register for the webinar to learn about the company's near-term milestones.
Read more →NRSN▼ -7.1%on this news
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
NeuroSense Therapeutics announced significant findings from its Phase-2b PARADIGM study, revealing that PrimeC treatment led to notable reductions in Alzheimer's disease-related microRNAs. These changes indicate a decrease in neuroinflammation and neurodegeneration. The results support PrimeC's potential as a disease-modifying therapy for Alzheimer's. The company plans to use these findings to inform future studies.
Read more →NRSNNeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NeuroSense Therapeutics announced positive initial results from its Phase 2 RoAD trial of PrimeC for Alzheimer's disease, showing improved brain-cell connectivity and a favorable safety profile. The trial, which utilizes patient-derived neurons, aims to evaluate the drug's safety and efficacy over 12 months. These findings support the mechanistic rationale for PrimeC and guide its development in treating Alzheimer's.
Read more →NRSN▲ +6.8%on this news
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
NeuroSense Therapeutics has announced a $500,000 private placement of ordinary shares at a 40% premium to the market price. This financing is aimed at supporting the company's ongoing activities and upcoming milestones. The placement is expected to close on September 8, 2025, and will help strengthen the company's balance sheet while minimizing dilution for shareholders.
Read more →NRSNHamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 25, 2025 ________________________ Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially
NeuroSense Therapeutics Ltd. has announced its Annual General Meeting of Shareholders scheduled for September 25, 2025, at its offices in Herzliya, Israel. The agenda includes appointing Somekh Chaikin as the company’s auditors for 2025, electing Ms. Christine Pellizzari to the board of directors, and re-electing Dr. Revital Mandil-Levin and electing Mr. Cary Claiborne to the board. Shareholders must be registered by August 22, 2025, to participate and vote on the proposals.
Read more →NRSN▼ -40%on this news
NeuroSense Provides Business Update and Progress for the First Half of 2025
NeuroSense Therapeutics has provided a business update for the first half of 2025, highlighting significant progress in its investigational therapy PrimeC for ALS. The company regained compliance with Nasdaq requirements and is preparing for a pivotal Phase 3 trial. Financial results show a reduced operating loss compared to the previous year, although the company still faces challenges with its accumulated deficit.
Read more →NRSNAward-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
NeuroSense Therapeutics CEO Alon Ben-Noon will join actor Aaron Lazar in a live podcast to discuss ALS and the company's investigational therapy, PrimeC. The event will cover NeuroSense's regulatory progress in Canada and its partnership with a pharmaceutical company. Participants can engage by submitting questions during the webcast.
Read more →NRSNNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
NeuroSense Therapeutics has successfully scaled up production of its ALS therapy, PrimeC, in preparation for a potential Canadian market launch. The company has enhanced its manufacturing capabilities and partnered with a global CDMO to ensure compliance and reliability. With a projected market opportunity of $100-150 million, NeuroSense aims to expedite access through Health Canada's regulatory pathway.
Read more →NRSNNeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
NeuroSense Therapeutics has released a letter to shareholders detailing its clinical progress and regulatory strategy for PrimeC in ALS. The company is optimistic about ongoing partnership discussions with a global pharmaceutical firm and is preparing to initiate a Phase 3 trial in late 2025. Positive results from previous studies validate PrimeC's efficacy, while discussions with Health Canada may lead to earlier access for patients in Canada.
Read more →NRSNNeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC
NeuroSense Therapeutics announced encouraging data from its Phase 2b PARADIGM trial for PrimeC, aimed at treating ALS. The findings reveal significant miRNA modulation and consistent downregulation of 161 miRNAs related to ALS, suggesting a potential to slow disease progression. PrimeC demonstrated previously reported clinical benefits, including a notable reduction in disease progression and improved survival rates. The results were presented at the AAN meeting, highlighting the therapy as a promising candidate in the fight against ALS.
Read more →NRSNNeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
NeuroSense Therapeutics reported its financial results for 2024, highlighting significant clinical progress with its lead drug candidate, PrimeC, in ALS treatment. The company completed a Phase 2b study showing promising results and received positive feedback from the FDA for advancing to a Phase 3 study. Despite a reported operating loss, the company is optimistic about its future growth.
Read more →NRSNNeuroSense Therapeutics to Present New Data from PrimeC
NeuroSense Therapeutics announced two upcoming presentations at the 77th Annual American Academy of Neurology Meeting, featuring new data from its Phase 2b trial of PrimeC, a novel therapy for ALS. Key findings will focus on PrimeC's safety, efficacy, and its potential to redefine ALS treatment through a multi-targeted approach. Two experts on NeuroSense's Scientific Advisory Board will explore both clinical outcomes and the underlying mechanisms of action related to microRNA modulation. The data presented highlights the promising advancements in ALS treatment, though associated regulatory and development uncertainties remain.
Read more →NRSNNeuroSense featuring the VP Quality and Compliance
The article features a personal account from the VP of Quality and Compliance at NeuroSense, who reflects on how ALS has impacted their life. The individual shares a poignant story about their grandfather's battle with the disease, emphasizing the motivation it provides in their professional role. This narrative underscores the importance of personal experiences in driving commitment to ALS research and treatment.
Read more →NRSNNeuroSense featuring the CRA
NeuroSense emphasizes a close-knit, collaborative work culture that sets it apart from larger pharmaceutical companies. Eidan Lushi, a Clinical Research Associate, highlights the importance of personal relationships and teamwork in clinical trials, particularly in the context of neglected diseases like ALS. The company prioritizes open communication and adaptability, fostering a sense of shared purpose among its team members.
Read more →NRSN▼ -5.8%on this news
NeuroSense featuring the VP Business Development
Nedira Salzman-Frenkel, VP of Business Development at NeuroSense, shares her journey and motivations in drug development, particularly for neurodegenerative diseases like ALS. She emphasizes the importance of adaptability in the ever-changing biopharma landscape and highlights the company's commitment to developing disease-modifying therapies. Salzman-Frenkel's personal connection to ALS drives her passion for improving patient lives.
Read more →NRSNNeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement NeuroSense in Compliance with all Nasdaq Listing Requirements
NeuroSense Therapeutics Ltd. has regained compliance with Nasdaq's minimum equity requirement after successfully raising new equity and reducing liabilities. The confirmation allows the company to continue trading under the symbol NRSN on the Nasdaq Capital Market. This achievement highlights NeuroSense's financial strength as it gears up for a pivotal Phase 3 study of its drug candidate, PrimeC, which has shown promise in previous trials for treating ALS. However, the company will be monitored for one year to ensure ongoing compliance with Nasdaq's listing rules.
Read more →NRSNNeuroSense featuring the Office Manager
NeuroSense's Office Manager, Bar Levin, highlights the positive and inclusive work environment at the company. She emphasizes the strong employee engagement and the supportive culture that fosters collaboration. Levin appreciates the thorough onboarding process that helps new employees feel valued and connected to the company's mission. The presence of many women in the workplace adds to the supportive atmosphere.
Read more →NRSN▼ -8.1%on this news
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study Additio
NeuroSense Therapeutics has entered into a binding term sheet with a leading global pharmaceutical company to advance PrimeC, its proprietary treatment for amyotrophic lateral sclerosis (ALS). The agreement outlines significant financial terms, including substantial upfront payment and funding for a Phase 3 study. PrimeC, which demonstrated positive safety and efficacy in earlier trials, is designed to target key mechanisms of ALS progression. Both parties will finalize a definitive agreement, expected in early 2025.
Read more →NRSNNeuroSense Provides Business Update and Third Quarter 2024 Financial Results
NeuroSense Therapeutics Ltd. announced a strong business update alongside its financial results for Q3 2024, highlighting the completion of its Phase 2b PARADIGM study, which indicated significant efficacy in slowing ALS progression with its treatment, PrimeC. The company received positive FDA feedback for its Phase 3 study design, and is preparing for an anticipated launch of PrimeC in Canada by 2026. Despite operational losses and a negative equity position, recent funding has bolstered its financial health, positioning the company for future growth and developmental milestones.
Read more →NRSNNeuroSense featuring the VP CMC
Sharon Cohen-Vered, VP of CMC at NeuroSense, expresses her deep commitment to the company's mission and the importance of progress in the biotech industry. She highlights her active role in the development of PrimeC, emphasizing teamwork and patient considerations. Despite the challenges of working in a startup, she finds the work fulfilling and impactful.
Read more →NRSN▼ -10.8%on this newsshared move
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phas
NeuroSense Therapeutics has received positive feedback from the FDA regarding the design of its proposed Phase 3 study for PrimeC, a treatment for ALS. The Type C meeting addressed the study's efficacy and safety measures, marking a significant milestone in the company's drug development process. NeuroSense plans to submit a final protocol to the FDA in early 2025 and aims to start patient enrollment in mid-2025. The Phase 3 study is expected to involve approximately 300 patients in a randomized, placebo-controlled design.
Read more →NRSNNeuroSense featuring the Head of HR
Keren Pushett, Head of HR at NeuroSense, shares her personal journey with ALS and how it fuels her passion for the company's mission. She discusses the growth of NeuroSense, the development of its HR department, and the positive impact of their therapy, PrimeC. Pushett emphasizes the importance of empathy and support within the team, especially during crises.
Read more →NRSN▼ -5.3%on this news
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS In participants who received PrimeC from the start of the 18-month study compared to those initial
NeuroSense Therapeutics has announced completion of the PARADIGM study, which demonstrated significant efficacy and survival benefits of PrimeC in treating ALS. An analysis of the 18-month data revealed nearly an 8-point improvement in ALS Functional Rating Scale-Revised scores and a 58% increase in survival rates for patients receiving PrimeC from the start. The promising results will be presented at an upcoming symposium, and further updates regarding FDA interactions are anticipated in the coming days.
Read more →NRSNNeuroSense featuring the CMO
Ferenc Tracik, the Chief Medical Officer of NeuroSense, reflects on his journey and the unique culture of the biotech startup. He highlights the importance of patient focus and innovation within the company. Tracik shares his passion for neuroscience and the value of overcoming challenges in the biopharma industry. NeuroSense's proprietary formulation, PrimeC, aims to significantly impact patient lives.
Read more →NRSN▲ +14.3%on this newsshared move
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
NeuroSense Therapeutics announced a $5 million private placement agreement with an investor and its CEO, aimed at purchasing ordinary shares and warrants. The shares are priced at a 25% premium to the recent market price, reflecting positive investor sentiment and confidence in the company's potential. The funds from this placement will be utilized for general corporate needs and working capital. The transaction is expected to close in December 2024.
Read more →NRSNNeuroSense featuring the COO
NeuroSense Therapeutics COO Hagit Binder emphasizes the importance of flawless execution in clinical studies. With a focus on ALS and Alzheimer's, Binder outlines her role in planning, site selection, and collaboration with clinical research organizations. She prioritizes patient convenience and effective communication to enhance study success.
Read more →NRSN▼ -7.1%on this newsshared move
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
NeuroSense Therapeutics will participate in the 2024 International Symposium on ALS/MND from December 6-8 in Montreal, Canada. The company will present findings from its Phase 2b PARADIGM trial of its drug candidate PrimeC, which aims to treat ALS. Notable presentations will include insights from leading ALS researchers on clinical outcomes and biomarker analysis that may enhance treatment strategies for the disease. This involvement underscores NeuroSense's dedication to advancing research in neurodegenerative diseases.
Read more →NRSNNeuroSense featuring the Lead CRA
Vered Sasson, Lead CRA at NeuroSense, discusses the importance of collaboration in clinical trials. With over two years at the company, she has led the Phase 2b PARADIGM study and now works in a cross-functional role. Her responsibilities include data management and ensuring compliance with regulatory guidelines, all aimed at advancing new drug development.
Read more →NRSNNeuroSense featuring the VP Regulatory Affairs
Diana Shtossel, VP of Regulatory Affairs at NeuroSense, discusses the challenges and rewards of navigating the regulatory landscape for drug approval. With a focus on helping patients with rare diseases like ALS, she emphasizes the importance of communication with regulatory agencies and the need for robust development plans. Despite budget constraints and complex regulations, Shtossel encourages perseverance in the face of challenges.
Read more →NRSNNeuroSense featuring the CFO
NeuroSense's CFO, Or Eisenberg, highlights the company's commitment to developing treatments for ALS patients. He discusses the financial strategies necessary to support their R&D efforts and the importance of maintaining investor interest. Despite the challenges faced by R&D firms, Eisenberg believes their work is vital for making a positive impact on patients' lives.
Read more →NRSNNeuroSense featuring the VP R&D
Shiran Zimri, VP of R&D at NeuroSense, reflects on her journey from academia to industry, emphasizing her commitment to ALS patients and the importance of collaboration. She highlights the successful IPO and the regulatory challenges faced by the company. Zimri is passionate about mentoring young women in science and believes in setting ambitious goals.
Read more →NRSN▲ +6.3%on this newsshared move
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission bas
NeuroSense Therapeutics has scheduled a Type C meeting with the FDA on November 6, 2024, to discuss the design of its Phase 3 trial for PrimeC, a potential treatment for ALS. This meeting is essential for finalizing the trial's design and preparing for a New Drug Application submission. PrimeC has demonstrated promising efficacy, with significant reductions in disease progression observed in prior trials. The company also plans to submit a regulatory dossier to Health Canada in Q2 2025, anticipating a decision by Q1 2026.
Read more →NRSN▲ +5.2%on this news· ran to +17% by day 3shared move
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment
NeuroSense Therapeutics announced promising results from its PARADIGM clinical trial of PrimeC, a treatment for ALS. The trial demonstrated significant improvements in key microRNAs, suggesting potential to alter the progression of the disease. Results indicated a 37.4% statistically significant slowing of disease progression compared to placebo, further underlined by a 96% continuation rate of treatment among participants. The development is seen as a critical step towards providing more effective therapeutic options for ALS patients.
Read more →NRSNNeuroSense featuring the Regulatory Affairs Director
Dorit Jacob, Regulatory Affairs Director at NeuroSense, discusses her role and the company's commitment to patient care. She emphasizes the importance of regulatory compliance and transparency with health authorities. Jacob highlights the challenges of bringing products to market while maintaining quality, and shares her professional tips for success in regulatory affairs.
Read more →NRSN▼ -12.2%on this news
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potentia
NeuroSense Therapeutics has updated its plans for early commercialization of its ALS treatment, PrimeC, in Canada, backed by positive results from its Phase 2b clinical trial. A submission for approval under Health Canada's NOC/c policy is anticipated in Q2 2025, with a regulatory decision expected by Q1 2026. The drug significantly reduced disease progression and improved survival compared to a placebo, making it a potential breakthrough for ALS. The company estimates a sizable market opportunity in Canada, with plans to pursue further regulatory approvals globally.
Read more →NRSNNeuroSense featuring the Scientific Project Manager
NeuroSense's Scientific Project Manager, Nitai Kerem, emphasizes the integration of AI in ALS research. The company collaborates with PhaseV and NeuroKaire to enhance data analysis and patient profiling for PrimeC treatment. While AI aids in exploring new insights, it remains a tool rather than a definitive solution. NeuroSense's small size allows for close involvement in research, promoting efficiency.
Read more →NRSNNeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial result
NeuroSense Therapeutics has initiated preparations to file for early commercialization of its ALS treatment, PrimeC, in Canada following favorable Phase 2b trial results. The treatment showed significant efficacy with a 36% reduction in disease progression and enhanced survival rates compared to placebo. The company aims to expedite access to PrimeC for ALS patients, believing it addresses urgent medical needs. However, the path to regulatory approval remains uncertain and may involve various risks and challenges.
Read more →NRSNNeuroSense featuring the CEO
NeuroSense Therapeutics, led by CEO Alon Ben-Noon, is nearing the conclusion of a successful Phase 2b clinical trial for its ALS treatment, PrimeC. The company aims to address the lack of effective therapies for ALS and is also expanding its focus to Alzheimer’s and Parkinson’s diseases. Ben-Noon emphasizes the importance of perseverance and innovation in overcoming challenges faced during development.
Read more →NRSNNeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
NeuroSense Therapeutics announced the acceptance of two abstracts detailing their drug candidate PrimeC at the upcoming 2024 NEALS Annual Meeting. The abstracts will present significant findings from the Phase 2b PARADIGM study, highlighting a 36% reduction in ALS disease progression and a 43% improvement in survival rates. Notable neurologists will present the data, underscoring the potential of PrimeC as a novel treatment for ALS. The company emphasizes its commitment to ALS research and the urgent need for effective therapies.
Read more →NRSNNeuroSense Therapeutics Ltd. Condensed Interim Unaudited balance sheets U.S. dollars in thousands June 30
NeuroSense Therapeutics Ltd. reported its financial results for the six months ending June 30, 2024, indicating a significant decrease in total assets and an operating loss of $6,024,000. The company noted that its current cash resources are inadequate for a full year of operations, raising concerns about future financing. Furthermore, the ongoing conflict in Israel could impact its clinical trials, although the company plans to continue its developments in neurological diseases. The financial statements highlight both an increase in equity and significant accumulated deficits, underscoring the company's precarious financial position.
Read more →NRSNNeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
NeuroSense Therapeutics has announced that it has regained compliance with NASDAQ's minimum bid price requirement, achieving a closing bid price of $1.00 or more for 10 consecutive business days. The CEO expressed satisfaction with this milestone and highlighted the company's upcoming Phase 3 trial for PrimeC, following positive results from the Phase 2b trial. However, the company also cautioned about inherent uncertainties and risks linked to their forward-looking statements.
Read more →NRSNNeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer
NeuroSense Therapeutics has secured a pivotal U.S. patent for PrimeC, its lead drug candidate aimed at treating ALS and Alzheimer's disease. The patent extends protection until 2042 and is based on promising clinical trial results that show significant efficacy in slowing disease progression and improving survival rates. PrimeC's formulation combines ciprofloxacin and celecoxib in a unique manner to enhance therapeutic synergy. Despite the positive developments, the company cautions about potential uncertainties and risks in future trials and regulatory processes.
Read more →NRSN▲ +17.1%on this news· ran to +29% by day 1
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
NeuroSense Therapeutics has received a notification from Nasdaq indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share. The company has until February 24, 2025, to regain compliance by maintaining this minimum price for a set number of consecutive trading days. While the notification does not impact the company's operational status or current trading activities, failing to meet compliance requirements could result in delisting from Nasdaq. NeuroSense plans to monitor its share price closely during this period.
Read more →NRSNNeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
NeuroSense Therapeutics Ltd. has announced a private placement to raise $600,000 through a sale of ordinary shares and warrants, involving participation from senior management. The purchase price is set at a 10% premium over the market price, reflecting confidence in the company's lead candidate, PrimeC, especially following positive Phase 2b PARADIGM study results. Funds from the placement will be utilized for corporate and working capital purposes. The offering is subject to closing conditions and regulatory exemptions.
Read more →NRSN▼ -10.5%on this news
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial 12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous res
NeuroSense Therapeutics has reported positive results from its Phase 2b clinical trial, PARADIGM, which evaluated the efficacy of PrimeC in ALS patients. The 12-month data demonstrated significant regulation of iron levels, correlating with improved survival rates and slowed disease progression. The results suggest PrimeC has the potential to be a transformative therapy for ALS, leading the company to consider advancing to Phase 3 trials. Further discussions with the FDA and potential development partners are ongoing.
Read more →NRSN▼ -19.1%on this news
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression NeuroSense to submit the 12-month data to FDA to disc
NeuroSense Therapeutics has announced positive results from its PARADIGM Phase 2b clinical trial of PrimeC, showing up to a 73% improvement in complication-free survival compared to placebo in ALS patients. The study demonstrated a statistically significant slowing of disease progression and improved survival rates. NeuroSense plans to submit the 12-month data to the FDA and other regulatory agencies to discuss next steps for PrimeC's development. These results underscore the potential of PrimeC as a promising treatment for ALS, a condition with few effective therapeutic options available at present.
Read more →NRSNNeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug
NeuroSense Therapeutics Ltd. announced promising results from the 12-month PARADIGM Phase 2b study of its drug PrimeC for ALS patients. The study showed a significant 36% improvement in ALSFRS-R scores and a 43% increase in survival rates for those treated with PrimeC compared to placebo. An additional analysis indicated up to a 63% improvement in survival rates and greater efficacy over treatment duration. These findings suggest PrimeC's potential as a disease-modifying therapy for ALS, highlighting the need for new treatment options in this patient population.
Read more →NRSN▼ -5.9%on this news
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-m
NeuroSense Therapeutics has released a corporate update and first quarter 2024 financial results, highlighting positive outcomes from its Phase 2b PARADIGM trial. The trial showed a 43% reduction in disease progression among high-risk ALS patients treated with PrimeC compared to placebo. The company anticipates additional results, including 12-month survival data and biomarker analyses, while also engaging with potential partners and preparing for an FDA meeting to discuss a new drug application. However, it faces financial challenges, reporting a net loss of $5.4 million for Q1 2024 and limited cash reserves.
Read more →NRSNNeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
NeuroSense Therapeutics Ltd. has received a delisting notice from Nasdaq for not meeting the minimum $2.5 million stockholders' equity requirement. In response, the company plans to appeal the decision by requesting a hearing before the Nasdaq Hearings Panel, which could grant an extension until December 18, 2024. NeuroSense aims to present its strategy to regain compliance at the hearing. This situation follows the company's focus on developing treatments for severe neurodegenerative diseases, highlighting the challenges it faces amid financial scrutiny.
Read more →NRSNINDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets as of
NeuroSense Therapeutics Ltd. has published its consolidated financial statements for the year ending December 31, 2023. The report indicates a concerning ongoing trend of financial losses and raises doubts regarding the company's future viability as a going concern. The firm reported a net loss of $10,107,000, up from previous losses, and noted an increase in current liabilities without a proportional increase in current assets. This financial instability may impact investor confidence moving forward.
Read more →NRSN▼ -6.6%on this news
Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 ________________________ Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invit
NeuroSense Therapeutics Ltd. has announced its annual general meeting of shareholders, scheduled for June 27, 2024, at its offices in Herzliya, Israel. Shareholders of record as of May 24, 2024, are invited to vote on proposals including a bonus plan for the CEO and the renewal of his employment agreement. The board of directors unanimously recommends voting in favor of these proposals. The meeting's details will be made available to shareholders around May 28, 2024.
Read more →NRSN▼ -6.5%on this newsshared move
Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend an Annual
NeuroSense Therapeutics Ltd. has announced its Annual General Meeting of Shareholders to take place on June 27, 2024, at their offices in Herzliya, Israel. The agenda includes the approval of a bonus plan for CEO Alon Ben-Noon and the renewal of his employment agreement. Shareholders are encouraged to vote either online or by mail to ensure their shares are represented. Further details will be provided in the Proxy Statement.
Read more →NRSNNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3 rd Annual ALS Drug Development Summit
NeuroSense Therapeutics (NRSN) announced that Dr. Shiran Zimri, VP of R&D, will present at the 3rd Annual ALS Drug Development Summit in Boston on May 22, 2024. Dr. Zimri's session will cover the promising findings from the PARADIGM phase 2b clinical trial, which demonstrated a statistically significant 43% reduction in disease progression among ALS patients treated with PrimeC. The company is optimistic about advancing PrimeC through regulatory pathways following positive feedback from the scientific community about its efficacy.
Read more →NRSNNeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense
NeuroSense Therapeutics has partnered with PhaseV to enhance the design of its upcoming Phase 3 trial for PrimeC, a treatment for ALS. PhaseV's advanced causal machine learning analysis predicts high success probabilities across various patient subgroups based on insights from NeuroSense's earlier Phase 2b study. The collaboration aims to ensure effective patient enrollment and optimize study design, while the recent Phase 2b results demonstrated encouraging efficacy and safety metrics for PrimeC. NeuroSense is preparing to submit its End of Phase 2 package to regulatory authorities.
Read more →NRSNNeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients PrimeC slowed disease progression by 43% (p=0.
NeuroSense Therapeutics has reported promising results from its Phase 2b PARADIGM clinical trial for PrimeC, indicating a significant 43% slowing of disease progression in high-risk ALS patients compared to placebo. The trial included a total of 68 participants across multiple countries, and additional subgroup analyses indicated consistent positive outcomes. Despite the encouraging data, uncertainties remain regarding the treatment's efficacy in the broader ALS population, as highlighted by mixed results in some analyses. The findings suggest potential advancements in ALS treatment if PrimeC successfully navigates further trials.
Read more →NRSNNeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. provided a business update highlighting key developments in Q1 2024. The company announced collaborations with Genetika+ and Lonza aimed at enhancing the research and treatment strategies for ALS and Alzheimer's disease. Positive data from the PARADIGM trial was presented at the American Academy of Neurology annual meeting, confirming effective safety and tolerability outcomes. Looking ahead, NeuroSense plans further collaborations and aims to transition into a Phase 3 clinical trial for its lead drug candidate, PrimeC.
Read more →NRSNNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer
NeuroSense Therapeutics has partnered with Genetika+ to enhance its Phase 2 clinical trial for Alzheimer's Disease. This collaboration employs Genetika+'s innovative technology to derive neurons from patients' blood, aimed at advancing drug development through better mechanistic understanding. NeuroSense's PrimeC therapy utilizes a multi-targeted strategy, which differentiates it from conventional AD treatments. Despite the optimistic potential of this partnership, there are inherent risks and uncertainties regarding the outcomes of the trial and collaboration.
Read more →NRSN▼ -5%on this newsshared move
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
NeuroSense Therapeutics presented positive data from its Phase 2b study of PrimeC at the American Academy of Neurology Annual Meeting. The study demonstrated significant clinical effects, including a 37% reduction in disease progression for ALS patients. Additionally, trends toward positive impacts on Neurofilament biomarker levels were observed, further supporting the potential of PrimeC as a treatment. The presentation was made by Dr. Merit Cudkowicz, which helps validate the study's findings and underscores the potential new approach for treating neurodegenerative diseases.
Read more →NRSNNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
NeuroSense Therapeutics Ltd. announced that it will present data from its PARADIGM Phase 2 study of PrimeC at the American Academy of Neurology Annual Meeting on April 16, 2024. Under the guidance of lead author Dr. Merit Cudkowicz, the presentation will focus on the drug's success in meeting primary and secondary endpoints in treating Amyotrophic Lateral Sclerosis (ALS). NeuroSense emphasizes its commitment to developing treatments for severe neurodegenerative diseases, which currently have limited therapeutic options. The company faces risks and uncertainties associated with the development and potential approval of PrimeC and other future trials.
Read more →NRSNNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
NeuroSense Therapeutics Ltd. has announced a $4.5 million funding initiative through a registered direct offering and a concurrent private placement. The deal involves the sale of nearly 3 million ordinary shares at $1.50 each, with warrants for additional shares. The proceeds are intended for working capital to support the company's R&D efforts for neurodegenerative disease therapies. While the funding represents a positive development, risks associated with clinical trials and regulatory processes remain.
Read more →NRSNApril 2024 Nasdaq: NRSN Forward - Looking Statements This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U . S . Private
NeuroSense, a biotechnology company, is presenting forward-looking statements regarding its ongoing clinical trials and the development of its product candidates. Highlights include significant results from a Phase 2b study for ALS, with future catalysts expected in H1 2024 related to biomarker results. However, the company acknowledges risks and uncertainties that could impact the actual outcomes of these trials, including potential delays in reporting results. The upcoming milestones and planned developments are centered around addressing the unmet needs in neurodegenerative diseases.
Read more →NRSNNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics NeuroSense will leverage its extensive experience in biomarker utilization
NeuroSense Therapeutics has announced a partnership with Lonza to identify exosome-based biomarkers to improve diagnostics and treatments for neurodegenerative diseases like ALS. This collaboration provides NeuroSense with access to Lonza's expertise and state-of-the-art laboratory capabilities, facilitating the development of their lead product candidate, PrimeC. The partnership aims to enhance early diagnosis and treatment options, potentially benefiting millions suffering from these conditions. Additionally, NeuroSense recently reported positive results from its Phase 2b clinical trial of PrimeC, indicating a significant slowing of disease progression in ALS patients.
Read more →NRSN▼ -17.5%on this newsshared move
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
NeuroSense Therapeutics Ltd. announced its financial results for the year ended December 31, 2023, highlighting significant progress in its Phase 2b ALS clinical trial, which showed safety and effectiveness. The trial's outcomes indicate potential improvements in patients' quality of life and survival without complications. However, the company reported a net loss of $11.3 million and experienced a decrease in cash reserves to approximately $2.6 million. NeuroSense's lead drug candidate, PrimeC, continues to be under development amid inherent market risks and uncertainties.
Read more →NRSNFebruary 2024 Nasdaq: NRSN Forward - Looking Statements This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U . S . Priva
NeuroSense Therapeutics presented forward-looking statements regarding their clinical strategies and timelines, emphasizing substantial risks and uncertainties inherent in these projections. Key highlights included substantial results from their Phase 2b trial for ALS and expectations for reporting neurofilament and biomarker results in the first half of 2024. Additionally, they noted the potential for partnership collaborations as they aim to address unmet needs in neurodegenerative diseases. However, challenges remain, including the risk of delays in achieving these clinical objectives.
Read more →NRSN▼ -8.8%on this newsshared move
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
NeuroSense Therapeutics reported positive results from its Phase 2b PARADIGM trial for PrimeC, its lead candidate for ALS treatment. The data indicate significant improvements in quality of life and complication-free survival compared to placebo. Additionally, PrimeC demonstrated a statistically significant slowing of disease progression, meeting pertinent efficacy endpoints. The results build on previous findings and suggest that PrimeC could be a meaningful therapeutic option for ALS patients.
Read more →NRSNNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts End of Phase 2 meeting with the FD
NeuroSense Therapeutics has reported a successful year in 2023, highlighting significant clinical achievements including a statistically significant reduction in disease progression for ALS patients in their Phase 2b trial of PrimeC. The company anticipates a series of crucial developments in 2024, including additional biomarker results and meetings with regulatory agencies. This progress may facilitate a pivotal Phase 3 trial for PrimeC, a combination therapy aimed at addressing the complexities of ALS treatment. Overall, NeuroSense is positioned for future advancements in treating neurodegenerative diseases.
Read more →NRSNNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital M
NeuroSense Therapeutics Ltd. announced it received notification from Nasdaq regarding its noncompliance with the minimum stockholders' equity requirement of $2.5 million. This notice, which does not affect the current trading of NeuroSense's shares, gives the company 45 days to present a plan for compliance. NeuroSense's CEO expressed optimism about recent positive results from the Phase 2b clinical trial for ALS, reaffirming the company's commitment to advance its treatments despite the financial challenges.
Read more →NRSNDecember 2023 Nasdaq: NRSN Forward - Looking Statements 2 This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U . S . Pri
NeuroSense's December 2023 presentation highlights the company's forward-looking statements related to their ALS Phase 2b clinical trial. The presentation indicates significant progress, including a promising top line result and an anticipated report on neurofilament and biomarker results early next year. However, the company acknowledges substantial risks and uncertainties that may impact the realization of these forward-looking statements, specifically mentioning potential delays in clinical and regulatory milestones. Additionally, NeuroSense aims to develop innovative therapies for neurodegenerative diseases, indicating potential market opportunities backed by strategic partnerships.
Read more →NRSN▲ +27.9%on this news
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in-ALSFRS-R, in patients treated with
NeuroSense Therapeutics has released promising data from its Phase 2b ALS trial (PARADIGM), showing a 37.4% statistically significant slowing of disease progression with its drug candidate PrimeC compared to placebo. This analysis included participants who adhered strictly to the trial protocol. The trial also met its primary safety and tolerability endpoints. Notably, 96% of participants who completed this segment of the trial chose to continue with PrimeC, which has been well-received within the ALS community.
Read more →NRSN▼ -24.2%on this news· ran to -51% by day 1
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on
NeuroSense Therapeutics Ltd. announced it will report topline results from the Phase 2b trial for its lead drug candidate PrimeC, targeting amyotrophic lateral sclerosis (ALS). This upcoming release includes primary safety and tolerability endpoints along with secondary clinical efficacy measures. The event is scheduled for December 5, 2023, and will be accompanied by a conference call for further insights. PrimeC has demonstrated positive results in earlier phases, gaining Orphan Drug Designation from the FDA and EMA.
Read more →NRSN▼ -24.2%on this news· ran to -51% by day 1
NeuroSense
NeuroSense Therapeutics announced top-line results from its Phase 2b PARADIGM trial for PrimeC in ALS, meeting primary safety and tolerability endpoints. The trial demonstrated a 29% difference in favor of PrimeC for the ALSFRS-R outcome and a positive trend for Slow Vital Capacity compared to placebo. Nearly all participants chose to continue treatment in an open label extension, and additional biomarker results are expected in early 2024. Despite promising data, the ALSFRS-R and SVC results lack statistical significance.
Read more →NRSN▲ +5.8%on this news· ran to +54% by day 3
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early Decembe
NeuroSense Therapeutics has announced its financial results for Q3 2023 and an update on its Phase 2b ALS trial. The company anticipates reporting topline clinical results in early December, which may provide critical insights into the efficacy and safety of its lead drug candidate, PrimeC. Participant continuity in the trial indicates strong patient engagement, and a recent FDA meeting has affirmed the company's development pathway for PrimeC. The firm is also advancing preparations for a Phase 2 Alzheimer's trial and has secured patents in various countries to protect its innovative therapies.
Read more →NRSNNeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in
NeuroSense Therapeutics has received confirmation from the U.S. FDA regarding its chemistry, manufacturing, and controls strategy for the drug PrimeC, which is being developed for amyotrophic lateral sclerosis (ALS). This confirmation is pivotal as it allows NeuroSense to progress toward a Phase 3 clinical trial. The current Phase 2b trial, PARADIGM, involves 69 ALS patients across multiple countries, and the company anticipates results for secondary endpoints soon. PrimeC has also been granted Orphan Drug Designation, enhancing its regulatory support as NeuroSense continues to focus on the urgent need for effective ALS treatments.
Read more →NRSNNeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
NeuroSense Therapeutics announced its participation in three upcoming ALS conferences, where key findings on its Phase 2b PARADIGM trial will be presented. The trial focuses on PrimeC, a treatment for amyotrophic lateral sclerosis (ALS), with results from the double-blind segment anticipated in December 2023. NeuroSense aims to utilize biomarker data to enhance understanding of PrimeC's efficacy. The company has previously shown promising results in a Phase 2a study, leading to further exploration of PrimeC's potential.
Read more →NRSN▲ +12.9%on this newsshared move
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 Clinical efficacy results (secondary endpoints) and safety results (
NeuroSense Therapeutics has announced the completion of dosing for the last patient in the double-blind segment of its Phase 2b ALS trial for the drug PrimeC. PrimeC targets mechanisms of neurodegeneration and has been granted Orphan Drug Designation by both the FDA and EMA. The company expects to release efficacy results from this segment of the trial in December 2023, and safety data in H1 2024. Additionally, PrimeC has shown promise in improving motor neuron survival in independent studies, indicating potential effectiveness for ALS treatment.
Read more →NRSNNeuroSense Therapeutics to Participate in BIO-Europe Fall
NeuroSense Therapeutics has announced that its Chief Medical Officer will attend the BIO-Europe Fall conference to discuss partnerships related to its drug development. The company's lead candidate, PrimeC, is currently in a Phase 2b study for ALS, following a successful previous phase. Additionally, NeuroSense has programs for Alzheimer's and Parkinson's diseases in various developmental stages, addressing significant medical needs amidst risks of operational uncertainties and trial delays.
Read more →NRSNNeuroSense CEO Provides Q3 2023 Update Phase 2b ALS topline results expected December 2023
NeuroSense Therapeutics has reported positive operational updates for Q3 2023, including the anticipation of Phase 2b ALS clinical trial topline results by December. The CEO emphasized the company's commitment to advancing treatments for severe neurodegenerative diseases despite challenges posed by recent regional violence. Notably, a non-sponsored study highlighted the effectiveness of their drug PrimeC. Additionally, NeuroSense is set to begin a Phase 2 trial for Alzheimer's disease and has received SME status from the European Medicines Agency.
Read more →NRSNNeuroSense CEO Provides Q3 2023 Update
NeuroSense Therapeutics provided a Q3 2023 corporate update, highlighting key developments in its clinical programs for ALS and Alzheimer's disease. The company anticipates reporting topline results from its Phase 2b ALS trial by December 2023. PrimeC has shown promising results in improving motor neuron survival in preclinical models. Despite the positive outlook, the company acknowledges potential risks associated with its forward-looking statements regarding clinical trials and result timelines.
Read more →NRSN▼ -7.9%on this news· ran to -24% by day 3
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase
NeuroSense Therapeutics has announced promising results from an in vitro study of its drug PrimeC, conducted at the University of Southern California. The study demonstrated significant improvements in motor neuron survival rates using PrimeC when compared to its individual components, suggesting a synergistic effect. Notably, PrimeC is positioned as a leading candidate for ALS treatment, with potential for further advancements in personalized drug screening. NeuroSense expects to release clinical top-line results from its Phase 2b study of PrimeC in the near future.
Read more →NRSNNeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results Topline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4
NeuroSense Therapeutics Ltd. has announced the termination of its at-the-market equity offering program, ensuring full funding through Q2 2024. The company is awaiting top-line clinical data from its ALS Phase 2b PARADIGM trial, which is expected in Q4 2023. In addition, NeuroSense plans to enroll patients in a new Phase 2 Alzheimer's disease study shortly. The founder expressed optimism about their PrimeC therapy's mechanism of action and the upcoming clinical results.
Read more →NRSNEuropean Medicines Agency Grants NeuroSense SME Status SME status offers regulatory guidance and engagement in dialogue with EMA NeuroSense to open an EU office in Ulm, Germany Company plans to enroll patients at multipl
NeuroSense Therapeutics Ltd. has announced opening an EU office in Ulm, Germany, and has received Small and Medium-Sized Enterprise (SME) status from the European Medicines Agency (EMA). This designation provides significant regulatory advantages, including guidance and fee reductions, as the company prepares to initiate a global pivotal Phase 3 study for PrimeC in ALS expected in 2024. Positive results from the ongoing Phase 2b PARADIGM trial are anticipated by the end of 2023. However, the company faces various inherent risks related to clinical timelines and financial challenges.
Read more →NRSNNeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023
NeuroSense Therapeutics has received patents for its ALS drug PrimeC from the European, Japanese, and Israeli Patent Offices, extending its intellectual property protections until 2038. This influential portfolio addition supports the company's commitment to treating ALS and similar neurodegenerative diseases. The company is also awaiting the topline results from its Phase 2b clinical trial, PARADIGM, due by the end of 2023. While there are significant advancements, there are intrinsic risks related to the timelines and efficacy of PrimeC.
Read more →NRSNNeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
NeuroSense Therapeutics Ltd. announced its participation in the 3rd International Pan-Asian Consortium for Treatment and Research in ALS (PACTALS) and the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) meeting. During these conferences, the company will present a poster focused on its ongoing PARADIGM Phase 2b ALS study. Notably, over 96% of trial participants opted to continue treatment with PrimeC, with topline results expected in Q4 2023. Despite the positive developments, management has acknowledged potential risks related to the clinical trial's outcomes.
Read more →NRSNInvestor Webinar September 2023 Nasdaq: NRSN Forward - Looking Statements This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of
NeuroSense Therapeutics held a webinar discussing forward-looking statements related to its product candidates and clinical trials. The company is highlighting its novel therapy PrimeC, aimed at treating ALS, and anticipates top-line results from the ongoing Phase 2b clinical trial in Q4 2023. The presentation emphasized the promising safety profile and efficacy of PrimeC observed in prior trials. Investor interest is driven by the product's potential in a market with significant unmet need and projected patient growth.
Read more →NRSNNeuroSense to Host Investor Webinar on September 12, 2023
NeuroSense Therapeutics Ltd. has announced an investor webinar on September 12, 2023, where its executive team will present the company's strategies and clinical trial updates. The webinar will feature discussions on NeuroSense's Phase 2b ALS trial and Phase 2 Alzheimer's disease study. Following a successful financing round, the company is well-positioned financially ahead of its upcoming trial data in Q4 2023. Interested investors can register for the event to engage with company executives directly.
Read more →NRSN▼ -5.2%on this news
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update ALS Phase 2b PARADIGM Trial Completed Patient Enrollment Topline results expected in Q-4 2023 Cash runway beyond topline clinical st
NeuroSense Therapeutics Ltd. announced its financial results for Q2 2023 and highlighted the successful completion of patient enrollment in its Phase 2b ALS study. CEO Alon Ben-Noon noted promising findings from biomarker studies which align with the company's clinical strategies. They raised $4.5 million, ensuring funding until Q2 2024, while topline results from the ALS trial are expected in Q4 2023. However, the company is facing significant financial challenges, including a net loss of $9.1 million and an accumulated equity deficit.
Read more →NRSNNeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
NeuroSense Therapeutics Ltd. announced it will host an investor event on July 24, 2023, at its U.S. office in Cambridge, Massachusetts. The event will feature presentations from key executives discussing the company's strategy, its Phase 2b ALS clinical trial, and upcoming catalysts. Topline results from the trial are expected in Q4 2023, with a significant majority of participants choosing to continue into an extension phase. As a clinical-stage biotech firm, NeuroSense aims to address the unmet needs in neurodegenerative diseases through combined therapies.
Read more →NRSNNeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit
NeuroSense Therapeutics announced its participation in two upcoming ALS-related conferences: the European Network to Cure ALS (ENCALS) and the EverythingALS Digital Biomarkers Summit. At these events, company leaders will engage with experts and researchers to advance treatment solutions for amyotrophic lateral sclerosis (ALS). The company emphasizes its commitment to collaboration in developing effective therapies for patients suffering from neurodegenerative diseases. However, the announcement also contains forward-looking statements that highlight the inherent risks and uncertainties involved in these endeavors.
Read more →NRSNNeuroSense CEO Provides Q2 2023 Update
NeuroSense Therapeutics has provided an update on its clinical and operational developments for Q2 2023. The company has completed patient enrollment for its Phase 2b PARADIGM trial for ALS and is awaiting topline results expected in Q4 2023. A strategic agreement with Biogen will evaluate PrimeC's effects on neurofilament levels. Additionally, the company is preparing for a Phase 2 trial concerning Alzheimer's Disease, while a biomarker study for Parkinson's Disease yielded statistically significant results, indicating potential for further development.
Read more →NRSNNeuroSense CEO Provides Q2 2023 Update View video here: Link
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has provided a second quarter update via CEO Alon Ben-Noon, highlighting key milestones achieved. The company completed patient enrollment for the 2b amyotrophic lateral sclerosis PARADIGM trial and has formed a scientific agreement with Biogen. Additionally, they are preparing for a trial focused on Alzheimer's disease and recently completed a Parkinson's disease biomarker study. NeuroSense raised $4.5 million, although they have noted potential risks related to delays in reporting trial results and other operational milestones.
Read more →NRSNCorporate Presentation June 2023 Nasdaq: NRSN Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Privat
NeuroSense Biopharma presented a corporate update in June 2023 that highlighted its development of PrimeC, a novel combination therapy for ALS. The company anticipates reporting top-line results from a Phase 2b clinical trial in Q4 2023 and is exploring collaborative advancements in Parkinson's disease therapies. They aim to address the unmet needs of ALS, where only three FDA-approved treatments exist. The presentation underscores both the risks associated with their forward-looking statements and the compelling market opportunity for ALS treatments.
Read more →NRSNNeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
NeuroSense Therapeutics reported its financial results for the first quarter of 2023 and provided updates on its ongoing business activities. The company has completed enrollment in its Phase 2b clinical trial for PrimeC, targeted at amyotrophic lateral sclerosis (ALS), with topline results expected in Q4 2023. A significant percentage of participants opted to continue treatment after the initial trial phase, reflecting potentially favorable outcomes. Additionally, NeuroSense's biomarker studies show promise for both Alzheimer's and Parkinson's diseases, yet the company faces financial challenges with a reported net loss and limited cash reserves.
Read more →NRSNNeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial 96% of participants who completed the trial opted to receive treatment with PrimeC in a 12-month open label extension Topline results expected Q4 2023
NeuroSense Therapeutics has completed enrollment in its Phase 2b clinical trial for PrimeC in patients with ALS. The trial, which involved 69 participants across multiple countries, has yielded strong retention rates with the majority opting for a 12-month open-label extension. Topline results are anticipated in Q4 2023, with the drug aiming to improve ALS symptoms through a novel combination mechanism. The development of PrimeC is supported by its Orphan Drug Designation from both the FDA and EMA.
Read more →NRSN▼ -20.1%on this news
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study Statistically significant decreased levels of novel biomarker AGO2 (p= 0.002) observed in newly diagnosed people living with Par
NeuroSense Therapeutics announced positive preliminary results from a biomarker study related to Parkinson's disease. The study revealed a statistically significant decrease in AGO2 levels among newly diagnosed PD patients compared to healthy controls. This finding is significant as it may help in targeting disease-specific pathways associated with PD. NeuroSense aims to further investigate these findings and collaborate with others focused on the development of therapies for Parkinson's disease.
Read more →NRSN▼ -5.2%on this news
Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 30, 2023 ________________________ Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite
NeuroSense Therapeutics Ltd. has announced its upcoming Annual General Meeting of Shareholders scheduled for May 30, 2023. The meeting is set to take place at their offices in Herzliya, Israel, at 11:00 a.m. local time. Shareholders of record as of April 24, 2023, are entitled to vote on the matters proposed, with detailed proxy voting instructions provided. The company's board is urging shareholders to participate in the voting process to ensure their shares are counted.
Read more →NRSNCorporate Presentation March 2023 Nasdaq: NRSN Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Priva
NeuroSense Therapeutics is preparing for significant developments in its ALS treatment pipeline, particularly with its combination therapy PrimeC. The company anticipates releasing top-line results from its Phase 2b trial in H2 2023. PrimeC is designed as a novel approach by combining two FDA-approved drugs to target multiple aspects of ALS pathology. However, the presentation also emphasizes the uncertainty and risks inherent in the company's forward-looking statements regarding clinical trial timelines and results.
Read more →NRSNNeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
NeuroSense Therapeutics announced significant progress in its Phase 2b ALS trial, achieving 80% patient enrollment, with topline results expected in the second half of 2023. The company is also preparing for a Phase 2 study in Alzheimer's disease following promising biomarker study findings. Additionally, a completed biomarker study in Parkinson's disease is set to yield results in early May. Despite these advancements, NeuroSense faces potential risks related to clinical trial timelines and the accuracy of its projections.
Read more →NRSNNeuroSense Therapeutics & Massachusetts General Hospital
NeuroSense Therapeutics has announced a collaboration with Massachusetts General Hospital's NeuroEpigenetics Lab to investigate the effects of its lead drug candidate, PrimeC, on amyotrophic lateral sclerosis (ALS). This partnership aims to explore PrimeC's mechanisms related to ALS pathology using advanced in vitro models. Dr. Zimri from NeuroSense is set to present preliminary results at the upcoming AD/PD 2023 conference. The company's Phase 2b clinical trial, named PARADIGM, is currently ongoing, with over 50% of participants enrolled and topline data expected in the second half of 2023.
Read more →NRSNNeuroSense to Present at the ALS and Alzheimer
NeuroSense Therapeutics announced that Dr. Shiran Zimri will present two studies at the AD/PD™ 2023 Advances in Science & Therapy Conference. The presentations will cover PrimeC as a potential disease-modifying treatment for ALS, with significant positive findings related to biomarkers from pre-clinical and Phase 2a trials. Additionally, NeuroSense is initiating a Phase 2 study for Alzheimer's Disease, highlighting its combination therapy's potential efficacy based on biomarker analysis. Results from these studies could lead to significant advancements in treatments for neurodegenerative diseases.
Read more →NRSNNeuroSense Announces Year End 2022 Financial Results and Provides Business Update
NeuroSense Therapeutics Ltd. reported its year-end 2022 financial results, highlighting continued progress in its lead ALS treatment, PrimeC, which is currently in the Phase 2b PARADIGM trial, with over 50% patient enrollment. The company also aims to initiate a Phase 2 trial for Alzheimer's disease following encouraging biomarker study results. However, it has withdrawn its protocol from the FDA to better align with regulatory expectations, which may impact its timeline. Additionally, the firm is focusing its North American recruitment efforts in Canada and plans to open clinical sites in the U.S. for pivotal studies.
Read more →NRSNNeuroSense Therapeutics to Participate in BIO-Europe Spring
NeuroSense Therapeutics Ltd. announced that its Chief Medical Officer and VP of Business Development will participate in the BIO-Europe Spring conference in Basel, Switzerland, aimed at seeking strategic partners. Their lead drug, PrimeC, is currently in a Phase 2b study for ALS, with topline results anticipated in the second half of 2023. Additionally, NeuroSense is progressing other programs targeting Alzheimer's and Parkinson's diseases. However, the company acknowledges the inherent risks and uncertainties regarding its forward-looking statements.
Read more →NRSNNeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts View video here
NeuroSense Therapeutics Ltd. provided a corporate update through a video from CEO Alon Ben-Noon, highlighting the company's accomplishments in 2022 and presenting growth opportunities for 2023. Key developments include upcoming topline results from its Phase 2b PARADIGM clinical trial in ALS and the initiation of a Phase 2 study in Alzheimer's disease. The company also expects to announce biomarker study results in Parkinson's disease soon. Despite the optimism, forward-looking statements indicate inherent risks that could delay proposed timelines and milestones.
Read more →NRSN▲ +13.2%on this newsshared move
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases QuantalX's direct electrophysiology imaging technology (Delphi-MD) expected to provide multiple clinically object
NeuroSense Therapeutics and QuantalX Neuroscience have announced a collaboration focused on advancing the early detection and treatment of neurodegenerative diseases. This partnership will utilize QuantalX's Delphi-MD technology in NeuroSense's upcoming Phase 2 clinical study for Alzheimer's disease, aiming to enhance diagnostic capabilities. The agreement also includes planning for future trials of NeuroSense's PrimeC for ALS. While the collaboration holds promise for improving patient outcomes, there are significant risks and uncertainties regarding trial timelines and the technology's performance.
Read more →NRSNNeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial PARADIGM protocol is approved in four countries: Israel, Italy, Canada, and Germany Topline results expected in H2 2023
NeuroSense Therapeutics has received approval from Germany's Federal Institute for Drugs and Medical Devices to begin enrolling patients in its Phase 2b ALS trial called PARADIGM. This trial will evaluate PrimeC, a combination of two FDA-approved drugs, in treating amyotrophic lateral sclerosis. The approval adds Germany to a list of countries where the trial is taking place. The company anticipates commencing enrollment in the coming weeks and aims to report topline results in the second half of 2023.
Read more →NRSNNeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study Receives regulatory approval from Health
NeuroSense Therapeutics has expanded its Phase 2b ALS PARADIGM trial to Canada following approval from Health Canada, allowing for patient enrollment. As over 50% of patients have been enrolled, topline results are anticipated later this year. However, the company has withdrawn its protocol from the U.S. Investigational New Drug application in response to FDA requests for additional non-clinical data, which will alter its clinical strategy aimed at a future pivotal Phase 3 study. This decision highlights both the progress in Canada and the regulatory challenges faced by the company.
Read more →NRSN▲ +76.2%on this news
NeuroSense Announces Second Quarter 2022 Financial Results and Provides Business Update
NeuroSense Therapeutics Ltd. has announced its financial results for the second quarter of 2022, highlighting advancements in its Phase IIb clinical trial for ALS. The company has successfully completed a significant milestone with the initiation of ALS biomarker studies, which yielded promising results. Despite facing substantial net losses, NeuroSense's cash position remains robust at over $10 million. Additionally, strategic collaborations are underway to enhance ALS monitoring using advanced technologies.
Read more →NRSN▲ +76.2%on this news
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination pla
NeuroSense Therapeutics has reported final results from its Alzheimer's biomarker study, highlighting elevated levels of TDP-43 in patients compared to healthy controls. Following preliminary findings, the study was expanded to include a larger control group to validate results. The company believes the significance of TDP-43 in Alzheimer’s pathology indicates the potential efficacy of its combination therapy technology in treating the disease. A Phase 2 double-blind clinical trial for this treatment is set to commence in the first half of 2023.
Read more →NRSNNeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update Mass., December 1, 2022 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial re
Read more →NRSNCorporate Presentation November 2022 Nasdaq: NRSN Disclaimer 2 This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U.S. P
1 Corporate Presentation November 2022 Nasdaq: NRSN Disclaimer 2 This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that invo
Read more →NRSN▲ +5.9%on this news
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS CAMBRIDGE, Mass., Nov. 16, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerativ
Read more →NRSN▲ +7.9%on this newsshared move
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy Follows a successful
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study CAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the U.S. Food
Read more →NRSNCorporate Presentation November 2022 Nasdaq: NRSN 1 Disclaimer 2 This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U.S.
Corporate Presentation November 2022 Nasdaq: NRSN 1 Disclaimer 2 This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that invo
Read more →NRSN▼ -8%on this news
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences. Conference: The 21st Annual NEALS M
Read more →NRSNNeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany
CAMBRIDGE, Mass, Oct. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering Conference on October 24-26, 2022 in L
Read more →NRSNNeuroSense Therapeutics Provides CEO
View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK CAMBRIDGE, Mass., Oct. 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and release
Read more →NRSNNeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on
NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City and analysts interested in participating in the Summit via webinar may register here: LINK Mass., October 12, 2022 -- NeuroSense Therapeutics Lt
Read more →NRSNNeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference
Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023 CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe
Read more →NRSN▲ +7.8%on this newsshared move
NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US Pharmacokineticic (PK) profile of PrimeC supports the formulation's extended release propert
NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US Pharmacokineticic (PK) profile of PrimeC supports the formulation's extended release properties, as the active components are released simultaneously
Read more →NRSNNeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial PrimeC is safe and tolerable at over 4x the maximal clinical dose Data support current Phase IIb PARADIGM s
NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial Mass., September 20, 2022 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, toda
Read more →NRSNCorporate Presentation August 2022 Nasdaq: NRSN Trademarks in this presentation are the property of their respective owners and used for informational and educational purposes only. 2 Disclaimer This presentation and ora
1 Corporate Presentation August 2022 Nasdaq: NRSN Trademarks in this presentation are the property of their respective owners and used for informational and educational purposes only. 2 Disclaimer This presentation and oral statements made regarding the subject of this presentat
Read more →NRSN▲ +7.4%on this news
NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study - NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to deve
NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study - NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments - NeuroSense's CEO to present at Everythin
Read more →NRSNNeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML NeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and m
NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML NeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and machine learning (ML) to identify and track oculometric d
Read more →NRSNNeuroSense Therapeutics CEO Provides Key Corporate Update Video View video here: https://youtu.be/KCT2wzOqmNo
NeuroSense Therapeutics CEO Provides Key Corporate Update Video video here: https://youtu.be/KCT2wzOqmNo CAMBRIDGE, Mass., July 18, 2022 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, toda
Read more →NRSNPrimeC Significantly Alters Key ALS Biomarkers Neuroinflammation TDP - 43 Accumulation Treated: Patients from NRSN Phase I Ia clinical trial who received PrimeC Non - treated: Matched patients on standard of care
PrimeC Significantly Alters Key ALS Biomarkers Neuroinflammation TDP - 43 Accumulation Treated: Patients from NRSN Phase I Ia clinical trial who received PrimeC Non - treated: Matched patients on standard of care
Read more →NRSN▼ -6.4%on this news· ran to -19% by day 3
Corporate Presentation July 2022 Nasdaq: NRSN 2 Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Priv
1 Corporate Presentation July 2022 Nasdaq: NRSN 2 Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve
Read more →NRSN▲ +23.4%on this newsshared move
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease CogniC is expected to
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative disease
Read more →NRSN▲ +47.1%on this news· ran to +99% by day 3shared move
NeuroSense Reports Positive Results from Stage III ALS Biomarker Study Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in co
Reports Positive Results from Stage III ALS Biomarker Study Stage III natural history study analyzed blood samples from people living with ALS, treated with standard of care. Preliminary results show that levels of disease-related biomarkers remain steady and unchanged in peopl
Read more →NRSN▲ +47.1%on this news· ran to +99% by day 3shared move
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense's Phase IIa study with PrimeC
Read more →NRSNNeuroSense CEO to be Panelist at Maxim Group
CAMBRIDGE, Mass, June 22, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's panel discussion on Innovations in ALS:
Read more →NRSNCorporate Presentation June 2022 Nasdaq: NRSN 2 Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Priv
1 Corporate Presentation June 2022 Nasdaq: NRSN 2 Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve
Read more →NRSNNeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC Pha se IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and s
NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC CAMBRIDGE, Mass., June 1st, 2022 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it h
Read more →NRSN▼ -5.4%on this newsshared move
NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update
NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update CAMBRIDGE, Mass., May 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today repor
Read more →NRSNNeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022
Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS" Phase IIb ALS study for NeuroSense's combination therapy PrimeC expected to commence Q2 2022 CAMBRIDGE, Mass., May 23, 2022 /PRNewswir
Read more →NRSNHamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 21, 2022 ________________________ Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invit
11 Hamenofim St., Building B, Herzliya 4672562, NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 21, 2022 ________________________ Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend an Annual General Meeting of Shareholders
Read more →NRSN▼ -7.6%on this news
Corporate Presentation May 2022 Nasdaq: NRSN Trademarks in this presentation are the property of their respective owners and used for informational and educational purposes only. 2 Disclaimer This presentation and oral s
1 Corporate Presentation May 2022 Nasdaq: NRSN Trademarks in this presentation are the property of their respective owners and used for informational and educational purposes only. 2 Disclaimer This presentation and oral statements made regarding the subject of this presentation
Read more →NRSN▼ -15.5%on this news· ran to -29% by day 3shared move
NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS Study conducted under FDA cleared protocol in parallel with international Phase IIb trial expected to commence in Q2
NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS conducted under FDA cleared protocol in parallel with international Phase IIb trial expected to commence in Q2 2022 Mass., April 11, 2022 -- NeuroSense Therapeutics Ltd. (Na
Read more →NRSN▼ -9.2%on this news· ran to -36% by day 3shared move
NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC
- Patent valid through 2038 - Phase IIb ALS trial expected to commence H1 2022 CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the
Read more →NRSN▼ -11.8%on this news
NeuroSense Therapeutics CEO Provides Key Corporate Update Video
NeuroSense Therapeutics CEO Provides Key Corporate Update Video CAMBRIDGE, Mass., March 30, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a video presentati
Read more →NRSN▼ -12.9%on this newsshared move
NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises - Warrants exercised at $6 per share - Extends cash runway through Q3 2023
Therapeutics Receives $4 Million Through Warrant Exercises Warrants exercised at $6 per share cash runway through Q3 2023 Mass., March 25, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenera
Read more →NRSN▲ +299.4%on this news
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS - PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa study - Phase IIb study expected to commence
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS - PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa study - Phase IIb study expected to commence Q2 2022 CAMBRIDGE, Mass., March 21, 2022 /PRNewswire/
Read more →NRSN▲ +5.3%on this news· ran to +17% by day 3
NeuroSense Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
CAMBRIDGE, Mass., March 15, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that the company's CEO, Alon Ben-Noon, has been invited to present at the 2022 Virtu
Read more →NRSN▲ +5.3%on this news· ran to +17% by day 3
Corporate Presentation March 2022 Nasdaq: NRSN Trademarks in this presentation are the property of their respective owners and used for informational and educational purposes only. 2 Disclaimer This presentation and oral
1 Corporate Presentation March 2022 Nasdaq: NRSN Trademarks in this presentation are the property of their respective owners and used for informational and educational purposes only. 2 Disclaimer This presentation and oral statements made regarding the subject of this presentati
Read more →NRSN▼ -18.1%on this news
NeuroSense Therapeutics Granted Key Patent for its ALS Drug PrimeC in Australia
CAMBRIDGE, Mass., March 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the grant of a key patent in Australia. The patent, which was already granted in the
Read more →NRSN▼ -8.5%on this news· ran to +39% by day 3shared move
NeuroSense Therapeutics to Present at American Society for Experimental Neurotherapeutics Annual Meeting on March 3rd
CAMBRIDGE, Mass., Feb. 24, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Dr. Shiran Zimri, the Company's Head of Scientific Programs, will deliver a pres
Read more →NRSNNeuroSense Therapeutics to Present at Aegis Virtual Conference
CAMBRIDGE, Mass., Feb. 22, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference
Read more →NRSNDisclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Private Securities Litigation Reform Act of 1995 tha
2 Disclaimer This presentation and oral statements made regarding the subject of this presentation contain "forward - looking statements" withi n the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All stateme
Read more →NRSN▲ +5.3%on this news
Hamenofim St., Building B, Herzliya 4672562, Israel NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 10, 2022 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend a Speci
11 Hamenofim St., Building B, Herzliya 4672562, NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 10, 2022 Dear NeuroSense Therapeutics Ltd. Shareholders: We cordially invite you to attend a Special General Meeting of Shareholders (the "Meeting"), of Neur
Read more →NRSN▲ +5.3%on this news
NeuroSense Therapeutics to Present at BIO CEO & Investor Conference
CAMBRIDGE, Mass., Jan. 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Alon Ben-Noon, NeuroSenses's CEO will present a company overview at the BIO CEO
Read more →NRSN▼ -13.2%on this newsshared move
NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts General Hospital - The new collaboration expands upon two successful partnered studies concluded in the recent year NEWS PROVIDE
NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts - The new collaboration expands upon two successful partnered studies concluded in the recent year NeuroSense Therapeutics January 27, 2022, 08:42 Cambridge, Massachusetts, January 27, 2022 Neuro
Read more →NRSN▼ -13.2%on this newsshared move
NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts General Hospital
CAMBRIDGE, Mass., Jan. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, announced today the initiation of the third stage of a collaborative biomarker study with Massachusetts Gene
Read more →NRSNNeuroSense Therapeutics, Ltd. Announces the Presentation of Phase IIa Study Results at Four International Conferences
CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that presentation of the company's Phase IIa clinical trial results have been accepted
Read more →NRSNNeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical Officer to Leadership Team
CAMBRIDGE, Mass., Dec. 21, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the appointment of four new directors up
Read more →NRSN▲ +9.3%on this news
NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market
CAMBRIDGE, Mass., Dec. 13, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd., (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, A
Read more →NRSNNeuroSense Therapeutics Announces Pricing of Initial Public Offering of Units and Approval to List on Nasdaq Capital Market NEWS PROVIDED BY NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Announces Pricing of Initial Public Offering of Units and Approval to List on Nasdaq Capital Market NeuroSense Therapeutics Ltd. December 08, 2021, 19:00 ET Cambridge, Massachusetts, December 08, 2021 NeuroSense Therapeutics Ltd., a clinical-stage bio
Read more →NRSNNeuroSense Therapeutics Publicly Files Registration Statement with SEC for Proposed U.S. Initial Public Offering
Cambridge, Mass., Oct. 19, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, announced today that it has publicly filed an
Read more →NRSNNeuroSense Therapeutics announces the appointment of Mark Leuchtenberger as Chairman of the Board
CAMBRIDGE, Mass., Sept. 29, 2021 /PRNewswire/ -- NeuroSense Therapeutics, a clinical stage biotechnology company in the field of CNS, is pleased to announce the appointment of Mark Leuchtenberger as its new Chairman of the Board of Directors. Mr. Leuchtenberger has over 25 years
Read more →Competitive Position
How NRSN ranks across every disease it competes inCompetitive Position is a premium feature
See how NRSN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial